Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Final analysis found olaparib was associated with a median overall survival of 51.7 months versus 38.8 months with placebo (HR 0.74 [95% CI 0.54–1.00]; p=0.054), unadjusted for the 38% of patients in the placebo group who received subsequent PARP inhibitor therapy.

Source:

The Lancet Oncology